• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Owens & Minor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    4/4/25 5:24:13 PM ET
    $OMI
    Medical Specialities
    Health Care
    Get the next $OMI alert in real time by email
    8-K
    OWENS & MINOR INC/VA/ VA false 0000075252 0000075252 2025-04-04 2025-04-04

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 4, 2025

     

     

    OWENS & MINOR, INC.

    (Exact name of Registrant as specified in charter)

     

     

     

    Virginia   001-09810   54-1701843

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    file number)

     

    (I.R.S. employer

    identification no.)

     

    10900 Nuckols Road, Suite 400

    Glen Allen, Virginia

      23060
    (Address of principal executive offices)   (Zip code)

     

    Post Office Box 27626,

    Richmond, Virginia

      23261-7626
    (Mailing address of principal executive offices)   (Zip code)

    Registrant’s telephone number, including area code (804) 723-7000

     

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $2 par value per share   OMI   New York Stock Exchange

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 1.01.

    Entry Into a Material Definitive Agreement.

    New Indenture and New Notes

    Overview

    On April 4, 2025, Owens & Minor, Inc. (the “Company”), completed its previously announced sale of $1,000,000,000 aggregate principal amount of the Company’s 10.000% senior secured notes due 2030 (the “New Notes”) in a private offering (the “Offering”) that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Offering was conducted in connection with the financing of the Company’s previously announced proposed acquisition (the “Acquisition”) of Rotech Healthcare Holdings Inc. (“Rotech”).

    At the closing of the Offering, the gross proceeds from the Offering (the “Escrow Property”) were placed into a segregated escrow account (the “Escrow Account”) where they will be held for the benefit of the holders of the New Notes pending the consummation of the Acquisition (such consummation date, the “Acquisition Date”). The proceeds will be released to fund the consummation of the Acquisition or in connection with the Special Mandatory Redemption (as defined below), as applicable. The terms of the New Notes are governed by the Indenture, dated April 4, 2025 (the “New Indenture”), by and among the Company, the guarantors named therein and Regions Bank, as trustee (in such capacity, the “Trustee”) and as collateral agent (in such capacity, the “Collateral Agent”).

    Interest; Ranking; Security; Guarantees

    The New Notes bear interest at a rate of 10.000% per year payable semi-annually in arrears on April 15 and October 15 of each year, commencing October 15, 2025. The New Notes are our general senior obligations and pending the consummation of the Acquisition and release of the Escrow Property, are secured by a first-priority lien on the Escrow Account. From and after the consummation of the Acquisition, the New Notes will be secured by a first-priority lien, subject to permitted liens and certain exceptions on substantially all of our and the guarantors’ existing and future assets other than excluded property that secure the Company’s credit facilities.

    The New Notes are pari passu in right of payment with any of our existing and future senior indebtedness, including indebtedness under the Company’s credit facilities and existing notes, senior in right of payment to any future subordinated indebtedness and structurally subordinated to any existing and future indebtedness and other liabilities of our subsidiaries that are not guarantors. From and after the consummation of the Acquisition (subject to any applicable grace periods), the New Notes will be pari passu as to the collateral owned by us with our indebtedness under the credit facilities and all of our future indebtedness secured by a first-priority lien on the collateral securing the New Notes, effectively senior to all of our existing and future unsecured indebtedness (including our existing notes) and junior lien obligations, to the extent of the value of the collateral securing the New Notes and effectively subordinated to any of our existing or future indebtedness that is secured by liens on assets that do not constitute a part of the collateral to the extent of the value of such assets.

    The New Notes are guaranteed by our existing and future wholly-owned domestic restricted subsidiaries (the “Initial Guarantors”) that guarantee or will guarantee our obligations under the Company’s credit facilities. From and after the consummation of the Acquisition and following the release of the Escrow Property, subject to any applicable grace period, the New Notes will be guaranteed by each of Rotech and Rotech’s existing and future wholly-owned domestic restricted subsidiaries that guarantee or will guarantee our obligations under the Company’s credit facilities (the “Post-Closing Guarantors,” collectively with the Initial Guarantors, the “Guarantors” and such guarantees provided by the Post-Closing Guarantors and the Initial Guarantors, the “Guarantees”).

    Special Mandatory Redemption

    If the Acquisition is not consummated on or prior to October 6, 2025, or upon the occurrence of certain other events, the Escrow Property will not be released to consummate the Acquisition and related transactions, but instead will be released to the Trustee for the purpose of redeeming the New Notes pursuant to a “Special Mandatory Redemption” in accordance with the procedures set forth in the New Indenture. The Special Mandatory Redemption price will be a price equal to 100% of the initial issue price of the New Notes plus accrued and unpaid interest to, but excluding, the special mandatory redemption date.

     


    Optional Redemption

    The Company may, at its option, redeem at any time and from time to time, all or part of the New Notes, prior to April 15, 2027, at a price equal to 100% of the principal amount of the New Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, plus a “make-whole” premium, as described in the New Indenture. On and after April 15, 2027, the Company may redeem all or part of the New Notes at the applicable redemption prices described in the New Indenture, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

    The Company may also redeem up to 40% of the aggregate principal amount of New Notes at any time prior to April 15, 2027, at a redemption price equal to 110% with an amount equal to or less than the net cash proceeds from certain equity offerings, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. At any time and from time to time, the Company may also redeem up to 10% of the aggregate principal amount of the New Notes issued under the New Indenture during each twelve-month period commencing from the date of release of the escrow funds, at a redemption price equal to 103% of the aggregate principal amount thereof, plus accrued and unpaid interest thereon to, but excluding, the redemption date.

    Prior to April 15, 2027, the Company may redeem the New Notes (including any additional notes issued under the New Indenture) with the net cash proceeds received by the Company from any disposition of the Products & Healthcare Services operating segment of the Company, solely to the extent that the operations and/or assets so disposed of constitute all or substantially all of the assets of the Company (a “PHS Disposition” and such redemption in connection with a PHS Disposition, a “PHS Disposition Redemption”) at a redemption price equal to 103% of the aggregate principal amount of the New Notes, plus accrued and unpaid interest thereon to, but excluding, the redemption date, in an aggregate principal amount for all such redemptions not to exceed the aggregate amount of the net available cash from such PHS Disposition.

    Change of Control

    Subject to certain limitations, in the event of a Change of Control (as defined in the New Indenture), the Company will be required to offer to repurchase the New Notes from holders at 101% (or in the case of a Non-Qualifying PHS Disposition (as defined in the New Indenture), 105%) of the principal amount thereof, plus accrued and unpaid interest, if any, to, but excluding, the purchase date. The occurrence of a Qualifying PHS Disposition will not constitute a Change of Control under the New Indenture.

    Covenants; Events of Default

    The New Indenture contains certain covenants, including, among other things, covenants that restrict the ability of the Company and its restricted subsidiaries to incur or guarantee additional indebtedness or issue disqualified stock or certain preferred stock, pay dividends and make other distributions or repurchase stock, make certain investments, create or incur liens, sell certain assets, enter into restrictions affecting the ability of restricted subsidiaries to make distributions, loans or advances or transfer assets to the Company or the guarantors, enter into certain transactions with the Company’s affiliates, designate restricted subsidiaries as unrestricted subsidiaries, and merge, consolidate or transfer or sell all or substantially all of the Company’s or the guarantors’ assets. These covenants are subject to a number of important limitations and exceptions. Most of these covenants will not apply to the Company and its restricted subsidiaries during any period in which the New Notes are rated investment grade by any two of Moody’s Investors Service, Inc., S&P Global Ratings and Fitch Inc.

    The New Indenture also contains customary provisions for events of default including, but not limited to, for failure to pay principal or interest when due and payable, failure to comply with covenants or agreements in the New Indenture or the New Notes and failure to cure or obtain a waiver of such default upon notice, failure of any liens created by the New Notes collateral documents on any material portion of the collateral intended to be covered to be valid and perfected, and events of bankruptcy, insolvency or reorganization affecting the Company and certain of its subsidiaries. In the case of an event of default, the principal amount of the New Notes plus accrued and unpaid interest, if any, may be accelerated.

    The description of the New Notes and the New Indenture in this Current Report on Form 8-K (this “Current Report”) are summaries and are qualified in their entirety by reference to the complete terms of the New Indenture and the form of New Notes included therein. The New Indenture and the form of global note representing the New Notes are filed hereto as Exhibits 4.1 and 4.2, respectively, and are incorporated by reference herein.

     


    PHS Disposition Paydown

    The New Indenture provides that the Company will not, and will not permit any of its restricted subsidiaries to, consummate any PHS Disposition unless, within five business days from the later of (A) the date such PHS Disposition is consummated and (B) the receipt of the aggregate net available cash from such PHS Disposition, an amount equal to at least 50% of the aggregate net available cash from such PHS Disposition is applied to reduce, prepay, repay or purchase the Company’s first lien obligations outstanding prior to the issuance of the New Notes pursuant to the Company’s term loan facility or any refinancing indebtedness in respect thereof.

     

    Item 2.03.

    Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

    The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

     

    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit    Description
    4.1    Indenture, dated April 4, 2025, by and among the Company, the guarantors named therein and Regions Bank, as trustee and as collateral agent.
    4.2    Form of Global Note for the 10.000% Senior Secured Notes due 2030 (included as Exhibit A to Exhibit 4.1 hereto).
    104    Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: April 4, 2025

     

    OWENS & MINOR, INC.
    By:  

    /s/ Heath Galloway

    Name:   Heath Galloway
    Title:   Executive Vice President, General Counsel and Corporate Secretary
    Get the next $OMI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMI

    DatePrice TargetRatingAnalyst
    7/19/2024$24.00 → $19.00Neutral → Buy
    Citigroup
    2/26/2024$24.00Market Perform
    Leerink Partners
    1/3/2024$21.00Equal Weight
    Barclays
    10/13/2022$52.00 → $18.00Buy → Neutral
    Citigroup
    10/12/2022$43.00 → $17.00Buy → Underperform
    BofA Securities
    10/12/2022$62.00 → $22.00Outperform → Neutral
    Robert W. Baird
    4/26/2022$55.00Buy
    Citigroup
    4/1/2022$43.00Neutral
    Credit Suisse
    More analyst ratings

    $OMI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Owens & Minor and Rotech Healthcare Mutually Agree to Terminate Previously Announced Acquisition

      OMI Remains Committed to Continued Growth in the Strong Home-based Care Market Will Focus on Deleveraging & Driving Profitable Growth Owens & Minor, Inc. (NYSE:OMI) today announced it has mutually agreed with Rotech Healthcare Holdings Inc. to terminate the previously announced acquisition. Under the terms of the merger agreement, Owens & Minor has paid $80 million to Rotech Healthcare. Owens & Minor will also redeem the $1 billion of notes issued in April 2025, which include a special mandatory redemption provision in accordance with their terms, and terminate the incremental term loan commitments and senior unsecured bridge loan commitments provided by our lenders which would have bee

      6/5/25 9:00:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Reports First Quarter 2025 Financial Results

      Top-Line Growth Led by the Patient Direct Segment Patient Direct Operating Margin Expanded by 173 Basis Points Company Reaffirmed 2025 Financial Guidance Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2025. "Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen e

      5/8/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Announces First Quarter 2025 Earnings Release Date and Conference Call

      Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the first quarter of 2025 on Thursday, May 8, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can b

      5/1/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Owens & Minor upgraded by Citigroup with a new price target

      Citigroup upgraded Owens & Minor from Neutral to Buy and set a new price target of $19.00 from $24.00 previously

      7/19/24 7:41:01 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Leerink Partners initiated coverage on Owens & Minor with a new price target

      Leerink Partners initiated coverage of Owens & Minor with a rating of Market Perform and set a new price target of $24.00

      2/26/24 8:10:20 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Barclays initiated coverage on Owens & Minor with a new price target

      Barclays initiated coverage of Owens & Minor with a rating of Equal Weight and set a new price target of $21.00

      1/3/24 8:05:34 AM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Owens & Minor Inc.

      SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

      11/12/24 10:32:12 AM ET
      $OMI
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Owens & Minor Inc. (Amendment)

      SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

      2/13/24 5:12:07 PM ET
      $OMI
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Owens & Minor Inc. (Amendment)

      SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

      2/12/24 5:29:41 PM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Financials

    Live finance-specific insights

    See more
    • Owens & Minor Reports First Quarter 2025 Financial Results

      Top-Line Growth Led by the Patient Direct Segment Patient Direct Operating Margin Expanded by 173 Basis Points Company Reaffirmed 2025 Financial Guidance Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2025. "Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen e

      5/8/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Announces First Quarter 2025 Earnings Release Date and Conference Call

      Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the first quarter of 2025 on Thursday, May 8, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can b

      5/1/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Reports Fourth Quarter & Full Year Financial Results and Announces Sale Process Underway for Products & Healthcare Services Segment

      Total Debt Reduction of $244 Million in 2024, Capping a Two-Year Total Debt Reduction of $647 Million 2025 Guidance Midpoint Indicates Double-Digit Adjusted EBITDA & Adjusted EPS Growth, and Improving Cash Flow Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services (P&HS) Segment Board of Directors Authorizes Share Repurchase Program of Up to $100 Million Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the fourth quarter and year ended December 31, 2024. "We are pleased with the progress that we have made against the strategy as outlined at our Investor Day in December 2023. As a reminder, we committed to optimizing our Prod

      2/28/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CHRO Stone Jennifer A covered exercise/tax liability with 5,764 shares, decreasing direct ownership by 5% to 110,327 units (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      6/4/25 4:39:16 PM ET
      $OMI
      Medical Specialities
      Health Care
    • EVP,General Counsel & CorpSecy Galloway Heath H covered exercise/tax liability with 1,768 shares, decreasing direct ownership by 1% to 117,044 units (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      5/20/25 7:55:01 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Director Rollins Carissa was granted 28,914 shares, increasing direct ownership by 116% to 53,902 units (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      5/16/25 6:11:21 PM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Coliseum Capital Management, Llc bought $3,073,750 worth of shares (410,000 units at $7.50) (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      4/10/25 9:43:55 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Large owner Coliseum Capital Management, Llc bought $4,291,218 worth of shares (528,356 units at $8.12) (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      4/7/25 8:21:15 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Large owner Coliseum Capital Management, Llc bought $27,386,158 worth of shares (2,893,412 units at $9.47) (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      3/4/25 9:07:16 PM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Leadership Updates

    Live Leadership Updates

    See more
    • Owens & Minor Names Tammy Gomez EVP and Chief Human Resources Officer

      Gomez assumes leadership of Owens & Minor's people strategy with a focus on cultivating talent that supports company performance Owens & Minor, Inc. (NYSE:OMI), a leading global healthcare solutions company, today announced the appointment of Tammy Gomez as Executive Vice President & Chief Human Resources Officer, effective July 11, 2022. Gomez will report to Owens & Minor's President and Chief Executive Officer, Edward A. Pesicka, and be a member of the company's executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005306/en/Owens & Minor names Tammy Gomez EVP and Chief Human Resources Officer, effect

      6/22/22 6:50:00 AM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    SEC Filings

    See more
    • SEC Form 8-K filed by Owens & Minor Inc.

      8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)

      6/6/25 4:30:28 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

      8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)

      6/5/25 9:12:33 AM ET
      $OMI
      Medical Specialities
      Health Care
    • SEC Form SD filed by Owens & Minor Inc.

      SD - OWENS & MINOR INC/VA/ (0000075252) (Filer)

      5/28/25 4:10:06 PM ET
      $OMI
      Medical Specialities
      Health Care